American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 140-146.e1 , January 2010

Two-Year Visual Results for Older Asian Women Treated With Photodynamic Therapy or Bevacizumab for Myopic Choroidal Neovascularization

  • Yasushi Ikuno

      Affiliations

    • Department of Ophthalmology, Osaka University Medical School, Osaka, Japan
    • Corresponding Author InformationInquiries to Yasushi Ikuno, Department of Ophthalmology E7, Osaka University Medical School, 2-2 Yamadaoka, Suita 565-0871, Japan
    • ,
  • Yoshimi Nagai

      Affiliations

    • Department of Ophthalmology, Kansai Medical University, Hirakata, Japan
    • Department of Ophthalmology, Osaka Dental University, Osaka, Japan
    • ,
  • Satoshi Matsuda

      Affiliations

    • Department of Ophthalmology, Osaka General Medical Center, Osaka, Japan
    • ,
  • Akiko Arisawa

      Affiliations

    • Department of Ophthalmology, Kansai Medical University, Hirakata, Japan
    • ,
  • Kenichiro Sho

      Affiliations

    • Department of Ophthalmology, Kansai Medical University, Hirakata, Japan
    • ,
  • Takashi Oshita

      Affiliations

    • Department of Ophthalmology, Osaka General Medical Center, Osaka, Japan
    • ,
  • Kanji Takahashi

      Affiliations

    • Department of Ophthalmology, Kansai Medical University, Hirakata, Japan
    • ,
  • Yasutaka Uchihori

      Affiliations

    • Department of Ophthalmology, Osaka General Medical Center, Osaka, Japan
    • ,
  • Fumi Gomi

      Affiliations

    • Department of Ophthalmology, Osaka University Medical School, Osaka, Japan

,Accepted 6 August 2009.

References 

  1. Sawada A, Tomidokoro A, Araie M, Iwase A, Yamamoto T Tajimi Study Group. Refractive errors in an elderly Japanese population: the Tajimi Study. Ophthalmology. 2008;115:363–370
  2. Cheng CY, Hsu WM, Liu JH, et al. Refractive errors in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci. 2003;44:4630–4638
  3. Tarczy-Hornoch K, Ying-Lai M, Varma R Los Angeles Latino Eye Study Group. Myopic refractive error in adult Latinos: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci. 2006;47:1845–1852
  4. Katz J, Tielsch JM, Sommer A. Prevalence and risk factors for refractive errors in an adult inner city population. Invest Ophthalmol Vis Sci. 1997;38:334–340
  5. Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology. 2006;1134–1141
  6. Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y Tajimi Study Group. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology. 2006;113:1354–1362
  7. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol. 1998;116:653–658
  8. Cotter SA, Varma R, Ying-Lai M, Azen SP, Klein R Los Angeles Latino Eye Study Group. Causes of low vision and blindness in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2006;113:1574–1582
  9. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110:1297–1305
  10. Pece A, Brancato R, Avanza P, et al. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol. 1995;18:339–344
  11. Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina. 1990;10:239–243
  12. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin (1-year results of a randomized clinical trial—VIP Report No. 1). Ophthalmology. 2001;108:841–852
  13. VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP Report No. 3. Ophthalmology. 2003;110:667–673
  14. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997;151:281–291
  15. Mason JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:685–688
  16. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–372
  17. Gomi F, Nishida K, Oshima Y, et al. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. Am J Ophthalmol. 2007;143:507–510
  18. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336–339
  19. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol. 2007;91:161–165
  20. Yamamoto I, Rogers AH, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157–160
  21. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147:94–100
  22. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2009;147:84–93
  23. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br J Ophthalmol. 2009;93:150–154
  24. Kojima A, Ohno-Matsui K, Futagami S, et al. Trans-Tenon's retrobulbar triamcinolone infusion for myopic choroidal neovascularization. Acta Ophthalmol Scand. 2006;84:749–754
  25. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91:1573–1581
  26. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol. 2004;138:434–438
  27. Lam DS, Chan WM, Liu DT, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow-up. Br J Ophthalmol. 2004;88:1315–1319
  28. Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2006;244:1474–1479
  29. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol. 2003;87:173–176
  30. Axer-Siegel R, Ehrlich R, Weinberger D, et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol. 2004;138:602–607
  31. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F. Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol. 2008;92:792–794
  32. Krebs I, Binder S, Stolba U, et al. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol. 2005;140:416–425

PII: S0002-9394(09)00570-4

doi: 10.1016/j.ajo.2009.08.008

American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 140-146.e1 , January 2010

Article Tools

* Image Usage & Resolution